Glaxo takeover bid for HGSI is doubling the stock this morning. This is a real good piece of news for the small cap biotech market today. I have a watch list of them, and like NBIX, they have all been getting beat up badly since the end of March. This could spark a reversal of that. Until more direct news comes out, NBIX will just follow the pack.
We will have the Phase III for Elagolix, the Phase IIb for the VMAT2, a phase II results for Elagolix for Uterine Fibroids to move the stock. Neurocrine is already partnering with Glaxo in Phase II projects for Cardiovascular and Stess-related Disorder drugs.